Human HEG1/HEG/MST112 ORF/cDNA clone-Mammalian (Non-Viral Vector) plasmid (NM_020733.2)

Cat. No.: pGMPC001509
Size: 10 µg
Concentration: generally 0.5ug/ul, usually not less than 0.3ug/ul
Leading Time: 3-7 working days

Pre-made Human HEG1/HEG/MST112 Non-Viral expression plasmid (overexpression vector) for mouse HEG1 overexpression in unique cell transient transfection and stable cell line development.

pdf Datasheet
pdf MSDS
pdf Terms of Use
Target products collection

Go to HEG1/HEG products collection>>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

Purchase
Shipping fee: Limited-time free
For payment issues, contact us.


Product Description

Catalog ID pGMPC001509
Gene Name HEG1
Accession Number NM_020733.2
Gene ID 57493
Species Human
Product Type Mammalian (Non-Viral Vector) plasmid (overexpression)
Insert Length 4146 bp
Gene Alias HEG,MST112,MSTP112
Fluorescent Reporter EGFP
Mammalian Cell Selection Null
Fusion Tag 3xflag (C-Terminal)
Promoter EF1
Resistance Amplicin
ORF Nucleotide Sequence ATGGCCTCGCCGCGCGCCTCGCGGTGGCCGCCGCCGCTCCTGCTGCTGTTGCTGCCGCTGCTGCTGCTGCCGCCGGCGGCCCCCGGGACGCGGGACCCGCCGCCTTCCCCGGCTCGCCGCGCGCTGAGCCTGGCGCCCCTCGCGGGAGCGGGGCTGGAGCTGCAGCTGGAGCGCCGCCCGGAGCGCGAGCCGCCGCCCACGCCGCCCCGGGAGCGCCGCGGGCCCGCGACCCCCGGCCCCAGCTACAGGGCCCCTGAGCCAGGCGCCGCGACACAGCGGGGACCCTCCGGCCGGGCCCCCAGAGGCGGGAGCGCGGATGCTGCCTGGAAACATTGGCCAGAAAGTAACACTGAGGCCCATGTAGAAAACATCACCTTCTATCAGAATCAAGAGGACTTTTCAACAGTGTCCTCCAAAGAGGGCGTGATGGTTCAGACCTCTGGGAAGAGCCATGCTGCTTCGGATGCTCCAGAAAACCTCACTCTACTCGCTGAAACAGCAGATGCTAGAGGAAGGAGCGGCTCTTCAAGTAGAACAAACTTCACCATTTTGCCTGTTGGGTACTCACTGGAGATAGCAACAGCTCTGACTTCCCAGAGTGGCAACTTAGCCTCAGAAAGTCTTCACCTGCCATCCAGCAGTTCAGAGTTCGATGAAAGAATTGCCGCTTTTCAAACAAAGAGTGGAACAGCCTCGGAGATGGGAACAGAGAGGGCGATGGGGCTGTCAGAAGAATGGACTGTGCACAGCCAAGAGGCCACCACTTCGGCTTGGAGCCCGTCCTTTCTTCCTGCTTTGGAGATGGGAGAGCTGACCACGCCTTCTAGGAAGAGAAATTCCTCAGGACCAGATCTCTCCTGGCTGCATTTCTACAGGACAGCAGCTTCCTCTCCTCTCTTAGACCTTTCCTCATCTTCTGAAAGTACAGAGAAGCTTAACAACTCCACTGGCCTCCAGAGCTCCTCAGTCAGTCAAACAAAGACAATGCATGTTGCCACCGTGTTCACTGATGGTGGCCCGAGAACGCTGCGATCTTTGACGGTCAGTCTGGGACCTGTGAGCAAGACAGAAGGCTTCCCCAAGGACTCCAGAATTGCCACGACTTCATCCTCAGTCCTTCTTTCACCCTCTGCAGTGGAATCGAGAAGAAACAGTAGAGTAACTGGGAATCCAGGGGATGAGGAATTCATTGAACCATCCACAGAAAATGAATTTGGACTTACGTCTTTGCGTTGGCAAAATGATTCCCCAACCTTTGGAGAACATCAGCTTGCCAGCAGCTCTGAGGTGCAAAATGGAAGTCCCATGTCTCAGACTGAGACTGTGTCTAGGTCAGTCGCACCCATGAGAGGTGGAGAGATCACTGCACACTGGCTCTTGACCAACAGCACAACATCTGCAGATGTGACAGGAAGCTCTGCTTCATATCCTGAAGGTGTGAATGCTTCAGTGTTGACCCAGTTCTCAGACTCTACTGTACAGTCTGGAGGAAGTCACACAGCATTGGGAGATAGGAGTTATTCAGAGTCTTCATCTACATCTTCCTCGGAAAGCTTGAATTCATCAGCACCACGTGGAGAACGTTCGATCGCTGGGATTAGCTACGGTCAAGTGCGTGGCACAGCTATTGAACAAAGGACTTCCAGCGACCACACAGACCACACCTACCTGTCATCTACTTTCACCAAAGGAGAACGGGCGTTACTGTCCATTACAGATAACAGTTCATCCTCAGACATTGTGGAGAGCTCAACTTCTTATATTAAAATCTCAAACTCTTCACATTCAGAGTATTCCTCCTTTTTTCATGCTCAGACTGAGAGAAGTAACATCTCATCCTATGACGGGGAATATGCTCAGCCTTCTACTGAGTCGCCAGTTCTGCATACATCCAACCTTCCGTCCTACACACCCACCATTAATATGCCGAACACTTCGGTTGTTCTGGACACTGATGCTGAGTTTGTTAGTGACTCCTCCTCCTCCTCTTCCTCCTCCTCCTCTTCTTCTTCTTCAGGGCCTCCTTTGCCTCTGCCCTCTGTGTCACAATCCCACCATTTATTTTCATCAATTTTACCATCAACCAGGGCCTCTGTGCATCTACTAAAGTCTACCTCTGATGCATCCACACCATGGTCTTCCTCACCATCACCTTTACCAGTATCCTTAACGACATCTACATCTGCCCCACTTTCTGTCTCACAAACAACCTTGCCACAGTCATCTTCTACCCCTGTCCTGCCCAGGGCAAGGGAGACTCCTGTGACTTCATTTCAGACATCAACAATGACATCATTCATGACAATGCTCCATAGTAGTCAAACTGCAGACCTTAAGAGCCAGAGCACCCCACACCAAGAGAAAGTCATTACAGAATCAAAGTCACCAAGCCTGGTGTCTCTGCCCACAGAGTCCACCAAAGCTGTAACAACAAACTCTCCTTTGCCTCCATCCTTAACAGAGTCCTCCACAGAGCAAACCCTTCCAGCCACAAGCACCAACTTAGCACAAATGTCTCCAACTTTCACAACTACCATTCTGAAGACCTCTCAGCCTCTTATGACCACTCCTGGCACCCTGTCAAGCACAGCATCTCTGGTCACTGGCCCTATAGCCGTACAGACTACAGCTGGAAAACAGCTCTCGCTGACCCATCCTGAAATACTAGTTCCTCAAATCTCAACAGAAGGTGGCATCAGCACAGAAAGGAACCGAGTGATTGTGGATGCTACCACTGGATTGATCCCTTTGACCAGTGTACCCACATCAGCAAAAGAAATGACCACAAAGCTTGGCGTTACAGCAGAGTACAGCCCAGCTTCACGTTCCCTCGGAACATCTCCTTCTCCCCAAACCACAGTTGTTTCCACGGCTGAAGACTTGGCTCCCAAATCTGCCACCTTTGCTGTTCAGAGCAGCACACAGTCACCAACAACAGTGTCCTCTTCAGCCTCAGTCAACAGCTGTGCTGTGAACCCTTGTCTTCACAATGGCGAATGCGTCGCAGACAACACCAGCCGTGGCTACCACTGCAGGTGCCCGCCTTCCTGGCAAGGGGATGATTGCAGTGTGGATGTGAATGAGTGCCTGTCGAACCCCTGCCCATCCACAGCCATGTGCAACAATACTCAGGGATCCTTTATCTGCAAATGCCCGGTTGGGTACCAGTTGGAAAAAGGGATATGCAATTTGGTTAGAACCTTCGTGACAGAGTTTAAATTAAAGAGAACTTTTCTTAATACAACTGTGGAAAAACATTCAGACCTACAAGAAGTTGAAAATGAGATCACCAAAACGTTAAATATGTGTTTTTCAGCGTTACCTAGTTACATCCGATCTACAGTTCACGCCTCTAGGGAGTCCAACGCGGTGGTGATCTCACTGCAAACAACCTTTTCCCTGGCCTCCAATGTGACGCTATTTGACCTGGCTGATAGGATGCAGAAATGTGTCAACTCCTGCAAGTCCTCTGCTGAGGTCTGCCAGCTCTTGGGATCTCAGAGGCGGATCTTTAGAGCGGGCAGCTTGTGCAAGCGGAAGAGTCCCGAATGTGACAAAGACACCTCCATCTGCACTGACCTGGACGGCGTTGCCCTGTGCCAGTGCAAGTCGGGATACTTTCAGTTCAACAAGATGGACCACTCCTGCCGAGCATGTGAAGATGGATATAGGCTTGAAAATGAAACCTGCATGAGTTGCCCATTTGGCCTTGGTGGTCTCAACTGTGGAAACCCCTATCAGCTTATCACTGTGGTGATCGCAGCCGCGGGAGGTGGGCTCCTGCTCATCCTAGGCATCGCACTGATTGTTACCTGTTGCAGAAAGAATAAAAATGACATAAGCAAACTCATCTTCAAAAGTGGAGATTTCCAAATGTCCCCGTATGCTGAATACCCCAAAAATCCTCGCTCACAAGAATGGGGCCGAGAAGCTATTGAAATGCATGAGAATGGAAGTACCAAAAACCTCCTCCAGATGACGGATGTGTACTACTCGCCTACAAGTGTAAGGAATCCAGAACTTGAACGAAACGGACTCTACCCGGCCTACACTGGACTGCCAGGATCACGGCATTCTTGCATTTTCCCCGGACAGTATAACCCGTCTTTCATCAGTGATGAAAGCAGAAGAAGAGACTACTTTTAA
ORF Protein Sequence MASPRASRWPPPLLLLLLPLLLLPPAAPGTRDPPPSPARRALSLAPLAGAGLELQLERRPEREPPPTPPRERRGPATPGPSYRAPEPGAATQRGPSGRAPRGGSADAAWKHWPESNTEAHVENITFYQNQEDFSTVSSKEGVMVQTSGKSHAASDAPENLTLLAETADARGRSGSSSRTNFTILPVGYSLEIATALTSQSGNLASESLHLPSSSSEFDERIAAFQTKSGTASEMGTERAMGLSEEWTVHSQEATTSAWSPSFLPALEMGELTTPSRKRNSSGPDLSWLHFYRTAASSPLLDLSSSSESTEKLNNSTGLQSSSVSQTKTMHVATVFTDGGPRTLRSLTVSLGPVSKTEGFPKDSRIATTSSSVLLSPSAVESRRNSRVTGNPGDEEFIEPSTENEFGLTSLRWQNDSPTFGEHQLASSSEVQNGSPMSQTETVSRSVAPMRGGEITAHWLLTNSTTSADVTGSSASYPEGVNASVLTQFSDSTVQSGGSHTALGDRSYSESSSTSSSESLNSSAPRGERSIAGISYGQVRGTAIEQRTSSDHTDHTYLSSTFTKGERALLSITDNSSSSDIVESSTSYIKISNSSHSEYSSFFHAQTERSNISSYDGEYAQPSTESPVLHTSNLPSYTPTINMPNTSVVLDTDAEFVSDSSSSSSSSSSSSSSGPPLPLPSVSQSHHLFSSILPSTRASVHLLKSTSDASTPWSSSPSPLPVSLTTSTSAPLSVSQTTLPQSSSTPVLPRARETPVTSFQTSTMTSFMTMLHSSQTADLKSQSTPHQEKVITESKSPSLVSLPTESTKAVTTNSPLPPSLTESSTEQTLPATSTNLAQMSPTFTTTILKTSQPLMTTPGTLSSTASLVTGPIAVQTTAGKQLSLTHPEILVPQISTEGGISTERNRVIVDATTGLIPLTSVPTSAKEMTTKLGVTAEYSPASRSLGTSPSPQTTVVSTAEDLAPKSATFAVQSSTQSPTTVSSSASVNSCAVNPCLHNGECVADNTSRGYHCRCPPSWQGDDCSVDVNECLSNPCPSTAMCNNTQGSFICKCPVGYQLEKGICNLVRTFVTEFKLKRTFLNTTVEKHSDLQEVENEITKTLNMCFSALPSYIRSTVHASRESNAVVISLQTTFSLASNVTLFDLADRMQKCVNSCKSSAEVCQLLGSQRRIFRAGSLCKRKSPECDKDTSICTDLDGVALCQCKSGYFQFNKMDHSCRACEDGYRLENETCMSCPFGLGGLNCGNPYQLITVVIAAAGGGLLLILGIALIVTCCRKNKNDISKLIFKSGDFQMSPYAEYPKNPRSQEWGREAIEMHENGSTKNLLQMTDVYYSPTSVRNPELERNGLYPAYTGLPGSRHSCIFPGQYNPSFISDESRRRDYF

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    Target Antibody GM-Tg-g-SE0258-Ab Anti-HEG1/ HEG/ MST112 functional antibody
    Target Antigen GM-Tg-g-SE0258-Ag HEG1 protein
    ORF Viral Vector pGMPC001509 Human HEG1 Mammalian (Non-Viral Vector) plasmid


    Target information

    Target ID GM-SE0258
    Target Name HEG1
    Gene ID 57493, 77446, 100424707, 689710, 101080319, 488015, 511689, 100070351
    Gene Symbol and Synonyms 4632417D23Rik,5530401I02Rik,9530025L16Rik,Gm629,HEG,HEG1,MST112,MSTP112,RGD1564641
    Uniprot Accession Q9ULI3
    Uniprot Entry Name HEG1_HUMAN
    Protein Sub-location Secreted Protein/Potential Cytokines
    Category Not Available
    Disease Not Available
    Gene Ensembl ENSG00000173706
    Target Classification Not Available

    Predicted to enable calcium ion binding activity. Involved in several processes, including negative regulation of Rho protein signal transduction; negative regulation of Rho-dependent protein serine/threonine kinase activity; and negative regulation of membrane permeability. Located in cell-cell junction. [provided by Alliance of Genome Resources, Apr 2022]



    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.